Osteoporosis drug shown to be as effective as Tamoxifen in preventing invasive breast cancer
On Apr. 17, 2006, the National Cancer Institute (NCI) announced initial results of the Study of Tamoxifen and…
On Apr. 17, 2006, the National Cancer Institute (NCI) announced initial results of the Study of Tamoxifen and…
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
On May 25, 1999. the Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer…
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
In 1998, Tamoxifen, created with the MCF-7 breast cancer cell line established by Karmanos, was revealed to reduce…
In 1973, Karmanos Cancer Institute researcher Herbert Soule, Ph.D. developed the MCF-7 human breast cancer cell line, which…